Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | CFD | P00746 | 2/20 | 0.41 |
| ▸ | F11 | P03951 | 2/20 | 0.41 |
| ▸ | TPSB2 | P20231 | 2/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7715446 | 0.73 | GAA (0.54) | GAAMEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL5335651 | 0.73 | LMNA (0.57) | DPP7GAAMEN1KMT2ALMNA | |
| SCHEMBL5305401 | 0.73 | LMNA (0.60) | GAAMEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL13568145 | 0.69 | GAA (0.47) | DPP7GAAMEN1KMT2ALMNA | |
| SCHEMBL7399278 | 0.68 | SCN9A (0.54) | GAAMEN1KMT2ALMNAALDH1A1 | |
| Iodide SCHEMBL7715449 | 0.68 | L3MBTL1 (0.58) | GAAMEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL7399275 | 0.68 | SCN9A (0.54) | GAAMEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL10712905 | 0.66 | LMNA (0.64) | GAAMEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL5092378 | 0.66 | LMNA (0.66) | DPP7GAAMEN1KMT2ALMNA | |
| SCHEMBL13948892 | 0.66 | ALDH1A1 (0.77) | GAAMEN1KMT2ALMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2009545549-A | — | — | 2009-12-24 | — | — | JP | claimed |
| US-20090312286-A1 | DERIVATIVES OF 4-TRIMETHYLAMMONIUM-3-AMINOBUTYRATE AND 4-TRIMETHYLPHOSPHONIUM-3-AMINOBUTYRATE AS CPT-INHIBITORS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2009-12-17 | — | — | US | claimed |
| EP-2046734-A1 | DERIVATIVES OF 4-TRIMETHYLAMMONIUM-3-AMINOBUTYRATE AND 4-TRIMETHYLPHOSPHONIUM-3-AMINOBUTYRATE AS CPT-INHIBITORS | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 2009-04-15 | — | — | EP | claimed |
| WO-2008015081-A1 | DERIVATIVES OF 4-TRIMETHYLAMMONIUM-3-AMINOBUTYRATE AND 4-TRIMETHYLPHOSPHONIUM-3-AMINOBUTYRATE AS CPT-INHIBITORS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2008-02-07 | — | — | WO | claimed |
| US-20100210695-A1 | COMPOSITIONS AND METHODS FOR TREATING SKIN DISORDERS | DARA BIOSCIENCES, INC. (US) | 2010-08-19 | — | — | US | disclosed |
| US-20090312286-A1 | DERIVATIVES OF 4-TRIMETHYLAMMONIUM-3-AMINOBUTYRATE AND 4-TRIMETHYLPHOSPHONIUM-3-AMINOBUTYRATE AS CPT-INHIBITORS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2009-12-17 | — | — | US | disclosed |
| EP-2046734-A1 | DERIVATIVES OF 4-TRIMETHYLAMMONIUM-3-AMINOBUTYRATE AND 4-TRIMETHYLPHOSPHONIUM-3-AMINOBUTYRATE AS CPT-INHIBITORS | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008015081-A1 | DERIVATIVES OF 4-TRIMETHYLAMMONIUM-3-AMINOBUTYRATE AND 4-TRIMETHYLPHOSPHONIUM-3-AMINOBUTYRATE AS CPT-INHIBITORS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210695-A1 | COMPOSITIONS AND METHODS FOR TREATING SKIN DISORDERS | CPT1B, CPT1A, CPT2 | DPP7 2343/4885GAA 1940/4885MEN1 4823/4885 |
| US-20090312286-A1 | DERIVATIVES OF 4-TRIMETHYLAMMONIUM-3-AMINOBUTYRATE AND 4-TRIMETHYLPHOSPHONIUM-3-AMINOBUTYRATE AS CPT-INHIBITORS | CPT1B, CPT1A, CPT2 | DPP7 160/4885GAA 1119/4885MEN1 4672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.